Shanghai Fosun Pharmaceutical (Group) Co., Ltd. SFOSF
2.14 USD 0.00 (+0.00%)
At closeNov 13, 2026, 4:00 PM EST
1.99 Day range 1.99
1.93 52-week range 3.30
- YTD
- -14.40%
- 1 year
- -35.15%
News
seekingalpha.com Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Q2 2026 Earnings Call Transcript
prnewswire.com Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the…
defenseworld.net Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest…
reuters.com Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
forbes.com Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment
seekingalpha.com Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.
seekingalpha.com Pandemic Accelerates China's Drive Into mRNA Treatments Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese…
seekingalpha.com Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun…
seekingalpha.com Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will…